Novartis has reported positive data from three Phase II trials which tested the efficacy of AIN457 (secukinumab) to treat moderate-to-severe plaque psoriasis.
AIN457 is a fully human, targeted monoclonal antibody that specifically binds to and neutralizes interleukin-17A (IL-17A), an inflammatory cytokine implicated in many immune-mediated diseases, including psoriasis.
The three double-blind, parallel group, placebo-controlled Phase II studies tested AIN457 in different doses and administration regimens.
In one study, 81% of patients receiving AIN457 150mg subcutaneously once a month experienced at least a 75% improvement of psoriasis signs and symptoms as measured by PASI (Psoriasis Area and Severity Index), as compared to 9% for placebo at week 12.
In another study, 83% of patients who were given an intravenous starting dose of AIN457 experienced at least a 75% improvement of symptoms vs 10% for placebo.
In the third study, AIN457 in the first month was beneficial to 55% of patients vs 2% for placebo at week 12.